Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome.
Overactive bladder syndrome is highly prevalent, particularly among the elderly. As well as the consequent morbidity, such as urinary infections, skin irritation and bone fractures, almost all aspects of quality of life, personal and social, are influenced. Therefore, the associated cost is substantial. Pharmacotherapy with antimuscarinics is the mainstay of treatment. Because of the good balance between efficacy, safety and tolerability, these drugs seem to be cost-effective therapeutic modalities for overactive bladder. In the milieu of a constantly ageing population, rising demand for the treatment of health conditions and the need for rational use of healthcare resources, further studies with long-term antimuscarinic drug treatment and follow-up are needed to redefine their therapeutic value.
Perimenis
Petros
P
Department of Urology, University Hospital, 26500 Patras, Greece. petperim@upatras.gr
Konstantinopoulos
Angelis
A
Giannitsas
Konstantinos
K
Athanasopoulos
Anastasios
A
D003362:Cost-Benefit Analysis; D006801:Humans; D018803:Models, Economic; D018727:Muscarinic Antagonists / Q000191:economics* / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D013577:Syndrome; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000209:etiology
D018727:Muscarinic Antagonists